Direct Comparison on Relapse Rates
Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) both significantly reduce annualized relapse rates (ARR) in relapsing multiple sclerosis (RMS), but head-to-head trials are lacking. Ocrevus shows slightly lower ARR in pivotal trials—0.02 for relapsing-remitting MS (RRMS) vs. Kesimpta's 0.10–0.11—but differences stem from trial designs, patient populations, and active comparators (interferon beta-1a for both).[1][2]
Real-world data and network meta-analyses suggest comparable efficacy. A 2023 analysis ranked Ocrevus highest for ARR reduction (80–90%), with Kesimpta close behind (75–85%), but no statistical superiority for either.[3]
How Trial Data Stacks Up
Ocrevus (OPERA I/II trials): ARR of 0.02 (46% relapses vs. placebo-adjusted), with 97% relapse-free at 96 weeks. Targets CD20+ B cells via infusion.[2]
Kesimpta (ASCLEPIOS I/II trials): ARR of 0.10 (ASCLEPIOS I) and 0.11 (II), 51–58% lower than Aubagio (teriflunomide). Self-administered subcutaneous injection.[1]
Kesimpta edged out on some MRI measures (new lesions), but Ocrevus had stronger disability progression data in primary progressive MS (not Kesimpta's label).[4]
Factors Beyond Relapse Rates
Relapse reduction isn't everything—Ocrevus reduces confirmed disability progression (CDP) by 24–40% more consistently across RMS and PPMS subtypes. Kesimpta matches on NEDA-3 (no evidence of disease activity) in some analyses but lacks PPMS approval.[3][5]
| Metric | Kesimpta ARR | Ocrevus ARR | Notes |
|--------|--------------|-------------|-------|
| Pivotal Trials | 0.10–0.11 | 0.02 | Different comparators[1][2] |
| Meta-Analysis Rank | Top 3–5 | #1 | Indirect comparisons[3] |
| CDP Reduction | ~30% | 24–40% | Ocrevus broader[4] |
Patient and Practical Tradeoffs
Kesimpta offers at-home dosing (monthly injection after loading) vs. Ocrevus' biannual infusions, potentially improving adherence. Both carry infection/ infusion reaction risks; Kesimpta has higher IgG reduction.[6]
No clear "better" for relapses alone—choice depends on MS type, progression risk, and lifestyle. Neurologists often pick Ocrevus for aggressive disease, Kesimpta for convenience.[7]
When Might One Outperform?